Trade Exelixis, Inc. - EXEL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.22 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 35.52 |
| Open | 35.84 |
| 1-Year Change | 59.64% |
| Day's Range | 35.8 - 36.41 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 21, 2025 | 35.52 | -0.24 | -0.67% | 35.76 | 36.49 | 35.29 |
| Apr 17, 2025 | 36.15 | 0.33 | 0.92% | 35.82 | 36.42 | 35.52 |
| Apr 16, 2025 | 35.95 | -0.09 | -0.25% | 36.04 | 36.50 | 35.68 |
| Apr 15, 2025 | 36.36 | 1.04 | 2.94% | 35.32 | 36.54 | 35.16 |
| Apr 14, 2025 | 35.56 | 0.00 | 0.00% | 35.56 | 35.90 | 35.06 |
| Apr 11, 2025 | 35.22 | 1.05 | 3.07% | 34.17 | 35.38 | 33.98 |
| Apr 10, 2025 | 34.40 | -0.16 | -0.46% | 34.56 | 34.84 | 33.12 |
| Apr 9, 2025 | 35.26 | 1.97 | 5.92% | 33.29 | 35.52 | 32.32 |
| Apr 8, 2025 | 34.05 | -1.21 | -3.43% | 35.26 | 35.67 | 33.57 |
| Apr 7, 2025 | 34.59 | 1.52 | 4.60% | 33.07 | 35.12 | 32.92 |
| Apr 4, 2025 | 34.34 | -1.36 | -3.81% | 35.70 | 36.23 | 34.25 |
| Apr 3, 2025 | 36.63 | 0.67 | 1.86% | 35.96 | 36.96 | 35.91 |
| Apr 2, 2025 | 36.99 | 0.95 | 2.64% | 36.04 | 37.08 | 35.76 |
| Apr 1, 2025 | 36.33 | -0.07 | -0.19% | 36.40 | 37.09 | 35.51 |
| Mar 31, 2025 | 36.71 | 0.54 | 1.49% | 36.17 | 37.05 | 35.48 |
| Mar 28, 2025 | 36.64 | 0.24 | 0.66% | 36.40 | 36.81 | 36.19 |
| Mar 27, 2025 | 36.73 | 0.05 | 0.14% | 36.68 | 38.07 | 36.45 |
| Mar 26, 2025 | 36.94 | -0.91 | -2.40% | 37.85 | 38.25 | 36.58 |
| Mar 25, 2025 | 37.67 | 0.07 | 0.19% | 37.60 | 38.13 | 37.08 |
| Mar 24, 2025 | 37.61 | 0.45 | 1.21% | 37.16 | 37.72 | 36.95 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Exelixis Company profile
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.| Industry: | Bio Therapeutic Drugs |
1851 Harbor Bay Parkway
ALAMEDA
CALIFORNIA 94502
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com